TORL BioTherapeutics is a clinical-stage biotechnology company dedicated to cutting-edge science to address the medical needs of cancer patients worldwide. Recognizing the diverse needs and experiences of cancer patients, the company focuses on ensuring equitable access to its therapies and fostering a supportive ecosystem that prioritizes holistic care.
TORL BioTherapeutics has raised $158 million in a Series B-2 funding round led by Deep Track Capital, with new participation from leading global biotechnology investors including RA Capital Management, Perceptive Advisors, and Avidity Partners as well as all existing biotechnology investors. In total, Torl has raised more than $350 million to date.
TORL BioTherapeutics, Culver City, California, United States, was founded in 2018. “We are grateful for the continued support from our existing world-class life sciences investors and are extremely pleased to add RA Capital Management, Perceptive Advisors, and Avidity Partners to the TORL team,” said Mark Alles, TORL’s Chairman and CEO. “This investment significantly enhances our opportunity to deliver multiple data-driven milestones from our novel antibody-based discovery platform and clinical-stage oncology drug development pipeline.”
